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Abstract: Fish acute toxicity tests are conducted as part of regulatory hazard identification and risk‐assessment packages for
industrial chemicals and plant protection products. The aim of these tests is to determine the concentration which would be
lethal to 50% of the animals treated. These tests are therefore associated with suffering in the test animals, and Organisation
for Economic Co‐operation and Development test guideline 203 (fish, acute toxicity) studies are the most widely conducted
regulatory vertebrate ecotoxicology tests for prospective chemical safety assessment. There is great scope to apply the 3Rs
principles—the reduction, refinement, and replacement of animals—in this area of testing. An expert ecotoxicology working
group, led by the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research, including
members from government, academia, and industry, reviewed global fish acute test data requirements for the major
chemical sectors. The present study highlights ongoing initiatives and provides an overview of the key challenges and
opportunities associated with replacing, reducing, and/or refining fish acute toxicity studies—without compromising envi-
ronmental protection. Environ Toxicol Chem 2020;39:2076–2089. © 2020 The Authors. Environmental Toxicology and
Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
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INTRODUCTION
Originally employed in the nineteenth century as a forensic
tool for investigating fish kills from effluent pollution, fish acute
toxicity tests have become a core requirement for prospective
safety assessment under many global regulatory frameworks for
manufactured chemicals, including plant protection products
(PPPs) and industrial chemicals (Table 1; Hunn 1989; Hutchinson
et al. 2016). They are used to determine the lethal concen-
tration of a substance that causes death in 50% of the test
population (LC50) during short‐term exposure—over hours or
days. Fish acute toxicity studies are now the most frequently
conducted vertebrate ecotoxicology tests (Figure 1; Burden
et al. 2017) and one of the very few standardized vertebrate
ecotoxicity tests where death is the intended endpoint—often
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TABLE 1: Fish acute toxicity data requirements by sector and global region, based on the Fish Toxicity Testing Framework (Organisation for
Economic Co‐operation and Development 2014) and Maynard et al. (2017)a
Industry sector Region Example legislation
Acute in vivo test required
for active substances
(yes/no)




EU European Commission (2013) Yes • Always required for rainbow trout
(Oncorhynchus mykiss, cold‐freshwater
species)
• Testing of products and ingredients,
where it cannot be predicted based on
ingredients, per Regulation 284/2013
North America US Federal Insecticide, Fungicide
and Rodenticide Act, Canadian
Plant Protection Product Active
Substances (Pest Management
Regulatory Agency)
Yes • Cold‐ and warm‐water freshwater species;
1 saltwater fish species, dependent on use
• Testing of ingredients only
Latin America Brazil (IBAMA): Portaria
Normativa IBAMA no. 84, de
15 de outubro de 1996
Yes • Cold freshwater, warm freshwater
dependent on country
• Testing of products and ingredients
Asia Pacific Japanese Agricultural Chemicals
Regulation; China, Ministry of
Agriculture and Rural Affairs:
e.g., Measures on the
Management of Pesticide
Registration and Measures for
the Administration of Pesticide
Labels and Manuals, and the
Data Requirements on
Pesticide Registration (defines
data required for submissions);
Republic of Korea, Ministry of
Agriculture, Food and Rural
Affairs: Pesticide Control Act
Enforcement Decree of the
Pesticide Control Act
Yes • In‐country testing may be required. For
example, only test reports obtained from
qualified testing facilities can be
recognized for registration review in
China. Unilateral acceptance of data
generated following OECD TGs to GLP
from overseas laboratories is not possible
unless there is a multilateral acceptance of
data agreement with China.
• Local fish species may be required to be
tested; e.g., in Bangladesh 2 local species
are required to be tested in‐country for
formulations. Some countries require
testing of specific species for specific uses;
e.g., in South Korea loach is required for
paddy uses.
• Testing of products and ingredients can
be required
Notes Estimated total number of different species tested in practice for global registration of an active substance = 4
(rainbow trout in the European Union, fathead minnow and sheepshead minnow in the United States, and
carp in Japan). Can be higher if multiple Asian countries require specific native species. Multiple additional
studies may be required, depending on the number of products requiring formulation testing.
Industrial
chemicals
EU European Commission (2006) Yes, if manufactured or
imported at
>10 tonnes/yr
Not specified; includes reference to species
included in OECD TG 203.
North America US industrial chemicals Toxic










Cold‐ and warm‐freshwater species; if a marine
or estuarine system may be affected,
saltwater species also generally required.




Act 1989; China New
Substance Registration—China
REACH—required by China's
Ministry of Ecology and
Environment
Yes • Cold freshwater or warm freshwater,
dependent on country; in‐country testing
may be required (e.g. China).
• State Environmental Protection
Administration, China, Guidelines for the
testing of chemicals, no. 203 fish acute
toxicity test (2004) requires freshwater
zebrafish (Brachydanio rerio)
Biocides EU EU Biocidal Products Regulation
(Regulation EU 528/2012)
Yes • One freshwater (+marine species, if
relevant)
• Testing of products and ingredients may
be required in some circumstances
depending on the use pattern, relative
sensitivity of other taxa compared to fish,
and if the risk cannot be predicted/
resolved based on the ingredients.
(Continued )
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causing significant suffering to test animals. This prompts
the question: What are the key opportunities to apply the
3Rs principles—reduction, refinement, and replacement (see
Table 2)—to the fish acute toxicity test in a regulatory setting?
Standardized protocols are followed when data from fish
acute toxicity studies are generated to meet regulatory require-
ments, including the Organisation for Economic Cooperation and
Development's (OECD's) test guideline 203 (Organisation for
Economic Co‐operation and Development 2019a) and the US
Environment Protection Agency's (USEPA's) test OCSPP
850.1075 (US Environment Protection Agency 2016a). Results are
most often submitted along with data on acute toxicity to in-
vertebrates and algae. For the prospective safety assessment of
chemicals (the scope of the present study), information is used for
hazard classification and labeling purposes and to assess risk to
fish potentially exposed to substances following their use or
discharge into the environment. It can also be used for non-
regulatory purposes or for internal company decision‐making,
such as molecule development and optimization, and to help
select concentration ranges for testing in longer‐term (chronic)
toxicity or bioaccumulation studies. Regulatory testing is
also conducted for the purposes of measuring water quality
TABLE 1: (Continued )
Industry sector Region Example legislation
Acute in vivo test required
for active substances
(yes/no)
Species required/recommended, and product/
formulation testing requirements
• Exemptions can apply to active substance
data, if 1) valid chronic (long‐term) fish
toxicity data are available or 2) in some
rare cases, if negligible exposure is
expected (attributable to the use pattern
or properties of the active substance)
North America Yes • Cold freshwater, warm freshwater, marine;
requirements can potentially be reduced
dependent on use or expected exposure
• Testing of ingredients
Asia Pacific Yes • Cold freshwater; requirements can
potentially be reduced dependent on use
or expected exposure or country
• Testing of products and ingredients
Notes For some product categories the data are already available from plant protection product registrations (e.g.,
certain fungicides and insecticides).
Human
pharmaceuticals







North America US Food and Drug
Administration Center for Drug
Evaluation and Research
Yes; action limit at
expected environmental
concentration >100 ng/L
(if not an endocrine‐
disrupting compound),
then a tiered approach if
Daphnia or algae risk
quotient <1000
Not specified
Notes For most global submissions, chronic testing conducted for EU submissions enables skipping of acute tiers of
US requirements; see Supplemental Data 1.
Cosmetics EU No, although information





Rest of world Country‐specific Dependent on country; requirement in China
for ingredients imported >1 tonne/yr to test
with a native species
Notes Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on
cosmetic products sets out a testing ban—prohibition on testing finished cosmetic products and cosmetic
ingredients on animals and a marketing ban, prohibition on marketing finished cosmetic products and
ingredients in the European Union which were tested on animals.
aNotably, testing in multiple species is required to register an agrochemical globally, whereas for human pharmaceuticals and cosmetics, minimal or no testing is
required.
GLP= good laboratory practice; IBAMA= Brazilian Institute of the Environment and Renewable Natural Resources; n/a = not applicable; OECD=Organisation for
Economic Co‐operation and Development; TG= test guideline.
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(e.g., effluent assessments), although this aspect is not the focus
of the present study.
Numerous ethical, scientific, business, and legislative drivers
are compelling a shift in the current safety‐assessment para-
digm away from established approaches, which largely rely on
the generation of data from whole‐animal (in vivo) studies
(Burden et al. 2015). Many legislations governing chemical
safety assessment, particularly in Europe, demand that verte-
brate animal tests are conducted as a last resort, that non-
animal methods are used where possible, and that existing
data are shared (e.g., European Commission 2006, 2009a,
2009b). Regional bans on the marketing of cosmetics con-
taining new ingredients tested on animals for human safety
assessment purposes have also come into force (e.g., Europe,
India, Israel and Brazil; European Commission 2009b; Burden,
et al. 2016a; Table 1). In 2019, a bold move was made by the
USEPA—the body responsible for regulating industrial chem-
icals and PPPs in the United States—by announcing its plan to
eliminate requests for mammalian safety tests by 2035 (US
Environment Protection Agency 2019). Efforts have already
started to reduce and refine mammalian acute toxicity tests
where they remain mandatory, for example, through activities
to modernize the USEPA's PPP data requirements (US
Environment Protection Agency 2017; Prior et al. 2019), dele-
tion of the OECD's acute oral toxicity test (test guideline 401;
Organisation for Economic Co‐operation and Development 1987)
in 2002 specifically because of animal welfare concerns, and the
recent adoption of OECD test guideline 433 (Organisation for
Economic Co‐operation and Development 2018) to increase the
use of more humane endpoints in place of death in acute in-
halation studies (Sewell et al. 2015, 2018). In nonmammalian
toxicology there have been similar efforts to improve the welfare
implications of avian acute toxicity testing, through introduction
and adoption of OECD test guideline 223 (avian acute oral
toxicity test) (Organisation for Economic Co‐operation and
Development 2016a). This test uses fewer animals than the
alternative method (OCSPP 850.2100) (US Environmental
Protection Agency 2012) and provides refinements, for example,
through the option for single‐dose limit testing where toxicity is
likely to be low (Edwards et al. 2017).
At the same time, there have been significant developments
in biomedical science which will impact how (eco)toxicology
and safety assessments are conducted in the future, together
with a greater focus on environmentally realistic exposure
scenarios. This includes the development of more sophisti-
cated and physiologically relevant cell‐based approaches and
the application of computational chemistry and mathematical
modeling to biological systems. There are many current efforts
focused on developing frameworks to allow data from these
newer, nonanimal approaches to be used in place of traditional
FIGURE 1: Number of Organisation for Economic Co‐operation and Development test guideline vertebrate ecotoxicology studies conducted
across 15 contract research organizations from 2014 through 2017. More information on this survey can be found in Burden et al. (2017). Fish acute
toxicity studies (in accordance with Organisation for Economic Co‐operation and Development 2019a) were by far the most frequently conducted.
TG= test guideline.
TABLE 2: Definitions of the 3Rsa
Standard Contemporary
Replacement Methods which avoid or replace the use of
animals
Accelerating the development and use of models and tools, based on the latest
science and technologies, to address important scientific questions without the
use of animals
Reduction Methods which minimize the number of
animals used per experiment
Appropriately designed and analyzed animal experiments that are robust and
reproducible and truly add to the knowledge base
Refinement Methods which minimize animal suffering
and improve welfare
Advancing animal welfare by exploiting the latest in vivo technologies and by
improving understanding of the impact of welfare on scientific outcomes
aFrom National Centre for the Replacement, Refinement and Reduction of Animals in Research (n.d.).
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in vivo results when making chemical safety decisions
(e.g., Organisation for Economic Co‐operation and
Development 2016b). There may also be a need to rethink
how decisions are arrived at as a result of changing environ-
mental factors (e.g., climate change) and the emergence and
evolution of new substance types (e.g., nanomaterials). Now is
the time to turn the focus on harnessing the opportunities to
improve the science underlying fish acute toxicity assess-
ments, while at the same time enabling traditional in vivo
approaches to be waived or replaced and, where still
absolutely necessary, to reduce or refine in vivo studies to
use fewer animals and/or induce less suffering—across all
geographic regions and industry sectors.
The present study has been prepared by the UK's National
Centre for the Replacement, Refinement and Reduction of
Animals in Research (NC3Rs) ecotoxicology expert working
group, following several discussions around the potential to
apply the 3Rs in fish acute toxicity testing. Firstly, in the section
Current State of the Science, Testing Frameworks, and Key
3Rs Opportunities, we identify pertinent areas for applying the
3Rs—including novel developments and existing opportunities
with scope for wider uptake across a range of regulatory sec-
tors. These are then summarized in the section Harnessing the
Opportunities, with specific examples of data analysis or other
work needed to clarify some of the uncertainties and enable
definitive improvements to fish acute toxicity testing and as-
sessment frameworks.
CURRENT STATE OF THE SCIENCE,
TESTING FRAMEWORKS, AND KEY
3Rs OPPORTUNITIES
Question 1: Are new fish acute toxicity data
always needed?
The first aspects to consider before carrying out any in vivo
test should be whether the data are relevant to the regulatory
and scientific question and whether data already exist that
could answer that question.
Are fish acute toxicity data needed at all? Exposure
considerations. In the “real world,” fish may rarely be ex-
posed to chemicals at high concentrations and/or within the
time frame of an acute toxicity test (which may better reflect an
accidental spill, inadequately treated discharge, or improper
disposal scenario). There may be limited uptake by fish if a
substance has certain physicochemical properties such as
low water solubility or a high melting point (Mayer and
Reichenberg 2006). Some substances are readily bio-
degradable (or highly labile), and exposure in the environment
may be very low following removal in wastewater‐treatment
plants, in regions where these exist. These properties can often
be readily identified, particularly if the substance will not dis-
solve (e.g., solid waxes), or by using modeling and analytical
means (e.g., Thomas et al. 2015). Evidence of no or very low
uptake may justify waiving acute in vivo tests in some regu-
latory regimes. Negligible release of a substance into the
environment would also lead to no or very low environmental
exposure (in the absence of spill events), or release may take
place over longer durations. In this case, results from chronic
tests may be more relevant. Human and veterinary medicinal
products are most likely to be present over the long term at low
levels because they mainly enter the environment following
patient use. Therefore, acute testing for European pharma-
ceutical registrations is only triggered when a predicted envi-
ronmental concentration reaches a threshold level, which has
been based on historical acute environmental toxicology data
(Table 1; European Medicines Agency 2006). This approach is
considered highly protective (Gunnarsson et al. 2019) and has
contributed in part to the practical removal of the requirement
for fish acute toxicity tests for pharmaceuticals. The European
Union's Registration, Evaluation, Authorisation and Restriction
of Chemicals (REACH) regulation for industrial chemicals also
uses a pseudo‐exposure‐driven approach because only sub-
stances produced or imported over 10 tonnes/yr require fish
acute toxicity data (Table 1). These “exposure‐driven” ap-
proaches are lacking in other legislation and regulations in-
cluding PPPs, where testing is in practice mandatory
irrespective of environmental exposure. A stronger focus on
exposure‐driven approaches has emerged in human health
safety assessment (National Research Council 2012; Sewell
et al. 2017a) and is equally applicable and beneficial to eco-
toxicology. Wider implementation of exposure rather than
hazard‐based assessments could greatly reduce the number of
vertebrate studies. Retrospective analysis of existing data
would help to determine suitable exposure triggers for testing
(per Gunnarsson et al. 2019). Evidence of low or negligible
exposure could at the very least help prioritize vertebrate
testing, if not all ecotoxicity testing. Future modeling efforts
should consider how chemical property and fate and effect
data may be effectively used to predict impacts from variable
exposure scenarios such as chemical spills.
Do data already exist to answer the scientific question?
Exploiting options to waive new experimental tests. Existing
data on the chemical or information on similar chemicals may be
available to conduct safety assessments without the need for new
data. The first step is to collate and review all available ecotoxicity,
fate, and physicochemical data. Fish acute data may not be
needed to characterize environmental risk if fish are not always
the most sensitive taxa for acute effects, as is the case for
many pharmaceuticals, industrial chemicals, and PPPs (Weyers
et al. 2000; Hutchinson et al. 2003; Jeram et al. 2005;
Rawlings et al. 2019; Lillicrap et al. 2020). Although many
regulatory regimes require ecotoxicity data across 3 trophic levels,
conducting tests using nonvertebrate species (i.e., invertebrates
and algae/aquatic plants) first may provide sufficient information
for safety assessment when considered with other data, partic-
ularly if the chemical falls into a class where potential toxic ef-
fects are well known (see section Grouping and read‐across
approaches). In chronic assessments of antibiotics, fish testing is
now not required because of the known lack of sensitivity
(Baumann et al. 2015; Brandt et al. 2015; Le Page et al. 2017;
Committee for Medicinal Products for Human Use 2018). Better
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understanding of evolutionary target conservation (i.e., bio-
logical similarity) across ecological taxa would be useful to de-
termine whether fish data are relevant. This has started to be
explored for the chronic effects of pharmaceuticals using tools
such as ECOdrug (n.d.; Gunnarsson et al. 2019).
Existing fish in vivo data, even with limitations or restrictions,
may be sufficient for decision‐making. Where regulations allow,
studies that do not adhere to a good laboratory practice (GLP)
framework or open literature studies may be used to consider
relative trophic‐level sensitivity or support assumptions of low
toxicity. All data should be evaluated in terms of reliability and
relevance (e.g., Moermond et al. 2016), in a way applicable to
the regulatory framework (Martin et al. 2019). Existing reliable
data on chronic fish toxicity may be relevant to acute effects or
support the assumption that fish are less sensitive than other
aquatic species. The European Union Biocidal Products Regu-
lation guidance already indicates that if a valid chronic study on
fish is available, acute data are not needed (European Chem-
icals Agency 2018). This can also be the case on a substance
registration–specific basis for industrial chemicals under the
European Union's REACH regulation (Annex VIII; European
Commission 2006). Existing data could also provide justifica-
tion for less animal‐intensive or refined acute toxicity studies
(e.g., application of an in vivo fish limit test, fish embryo acute
toxicity test [FET], or fish in vitro cell line assay; discussed in the
section Embryo and in vitro assays).
Grouping and read‐across approaches. Existing data on
substances that fall within the same “group” as the test
substance can be useful. Grouping is based on, for example,
structural similarities or the sharing of common metabolic
pathways. These properties can be used to predict likely phys-
icochemical, fate, and ecotoxicity profiles, the principle being
that the group of substances will exert similar effects. For ex-
ample, the PETROTOX model has been developed to perform
aquatic hazard assessment of petroleum substances based on
substance composition (Redman et al. 2017). Here, hydro-
carbons of similar structure and size within a petroleum sub-
stance are grouped together because they are known to behave
similarly in terms of environmental distribution and fate
(Concawe 1996). Toxicity or environmental risk limits of these
complex mixtures can then be calculated without the need for all
components to be tested experimentally.
A similar approach involves read‐across of experimental
data from one substance (source) to another (target); for an
example, see Supplemental Data 2. It is already possible to use
read‐across for classification and labeling purposes in the
European Union if fish acute data are not available (European
Chemicals Agency 2017a). Significant documentation is re-
quired to justify the validity of grouping or source data and
demonstrate the relevance of the grouping or read‐across
approach, as set out, for example, by the European Chemicals
Agency (2008, 2017b), and the OECD (Organisation for
Economic Co‐operation and Development 2017a). One draw-
back with read‐across approaches is that they cannot be used
where there are no existing experimental toxicity data for a new
chemical class to read‐across from. In addition, when
considering read‐across for risk management, the uncertainties
associated with it may prove unfavorable.
Question 2: Can standard fish acute toxicity
studies be replaced?
Information on fish acute toxicity will often be necessary to
enable safety assessment and environmental protection. But
must this always come from traditional in vivo studies? Wording
in the recently revised test guideline 203 (Organisation for
Economic Co‐operation and Development 2019a) suggests
that existing in vivo data as well as data from alternative ap-
proaches should be considered prior to conducting a full test
guideline 203 test. Several alternative/replacement approaches
which could provide useful data exist or are under develop-
ment. These include predictive computational tools or in silico
methods, such as quantitative structure–activity relationship
models (QSARs), or experimental techniques which do not
require the use of protected animals (defined as vertebrate
animals used for scientific purposes, protected under legis-
lation such as European Union Directive 2010/63 [European
Commission 2010], including early life‐stage embryos).
Computational models. A QSAR is a statistical model used
to relate a substance's structure to toxic outcomes. Such
models have started to be used in a regulatory context to
predict fish acute toxicity. The majority of QSARs conducted for
lower‐tier endpoints under the European Union REACH regu-
lation were for this purpose (European Chemicals Agency
2017c), and regulatory agencies themselves have developed
models, such as the ECOlogical Structure Activity Relationships
(ECOSAR) Class Program provided by the USEPA. The
ECOSAR program was used to assess the utility of QSARs in
predicting fish acute toxicity of PPP metabolites and was shown
to be a robust approach worthy of further investigation, with
potential for use in regulatory decision‐making (Burden et al.
2016b). There is already one example in Europe where
ECOSAR was used to estimate the toxicity of metabolites of the
biocidal active substance imiprothrin (European Chemicals
Agency 2018). Although this is promising, substances can only
be assessed using QSARs if they fall into one of the chemical
classes for which the model has been validated. Their use for
chemicals with novel chemistries is limited until experimental
data are available and subsequently incorporated into the
models. Further, significant documentation describing the
QSAR inputs and model is required to justify the prediction
before QSAR endpoints will be considered in a regulatory
setting (e.g., see European Chemicals Agency 2008).
Other computational models that could prove useful include
the USEPA's Interspecies Correlation Estimation platform (US
Environmental Protection Agency 2016b). These models esti-
mate the acute toxicity of a chemical to a species, genus, or
family with no test data (the predicted taxon) from the known
toxicity of the chemical to a species with test data (the surro-
gate species). Invertebrate data could therefore be used to
make predictions of fish acute toxicity without conducting a fish
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test, although further work will be needed to support such ex-
trapolations for regulatory acceptance. Alternatively, where
experimental data are available for one fish species, they could
be used to 1) extrapolate to other fish species (particularly
valuable for sectors where multiple species currently require
testing; see section Embryo and in vitro assays and Table 1)
and/or 2) aid in evaluation of interspecies variability for refine-
ment of risk assessments (European Food Safety Authority
2013). The Sequence Alignment to Predict Across Species
Susceptibility tool is another promising approach which could in
future be used in a regulatory context to support extrapolation
of toxicity information across species (LaLone et al. 2016).
Embryo and in vitro assays. Prior to embryos becoming
free‐feeding, they are considered to be incapable of experi-
encing pain, distress, suffering, or lasting harm (European
Food Safety Authority 2005) and in many regions are not
protected under animal welfare legislation in the same way as
juvenile and adult fish (e.g., European Commission 2010).
Their use is therefore considered beneficial from a 3Rs per-
spective, and the potential for fish embryo assays such as the
FET to be used in place of studies conducted at later life
stages has been extensively investigated. A version of the FET
is already used in Germany to assess the fish acute toxicity of
effluents (International Organization for Standardization 2007;
Bundesministerium für Umwelt, Naturschutz und nukleare Si-
cherheit 2009; Lillicrap et al. 2016). For prospective chemical
assessment there is an internationally validated method
(OECD test guideline 236; Organisation for Economic Co‐
operation and Development 2011a, 2011b, 2012, 2013). Results
have correlated well with standard in vivo fish acute LC50 data
for most chemicals tested (Braunbeck et al. 2005; Lammer
et al. 2009; Knöbel et al. 2012; Belanger et al. 2013; European
Commission 2014). Belanger et al. (2013) indicated that the high
correlation observed between the FET and traditional fish acute
toxicity studies was similar to that seen for traditional LC50
values generated between different species of fish, further
supporting the robustness of the approach. The broad regu-
latory applicability of this assay has, however, been questioned
(European Chemicals Agency 2016; see next section).
Great investment has also been made in developing in vitro
cytotoxicity assays. The rainbow trout RTgill‐W1 cell line assay
(International Organization for Standardization 2019; and OECD
test guideline development in progress) demonstrates a good
correlation with published in vivo LC50 endpoints for 35 chem-
icals with a range of properties and modes of action (Tanneberger
et al. 2013). It has been shown to be robust and reproducible
following a large‐scale international interlaboratory ring test
(Fischer et al. 2019). The applicability domain of the assay has
started to be characterized. For example, the acute toxicity of
fragrance chemicals has been accurately demonstrated (Natsch
et al. 2018), but the assay is known to be unsuitable for detecting
acute toxicity to certain neurotoxicants such as those which act
directly via brain tissue. Like many in vitro test systems, it has
limited metabolic capacity (Tanneberger et al. 2013), although
efforts are being made more widely to increase its metabolic
competence and utility (e.g., Luckert et al. 2017).
Replacement opportunity: Applying weight‐of‐
evidence approaches
By nature, whole‐organism tests incorporate biological
complexity; and in reality, no single nonanimal or alternative
method can be used in isolation to replace this. It is natural for
registrants and assessors to continue to use the “tried and
trusted” (and legally mandated) methods such as in vivo fish
acute toxicity tests, with which they are most familiar and for
which data interpretation is relatively straightforward. There is
still a need to build confidence in the use and interpretation of
data from alternative methods despite them being validated to
a high standard—greater than that of many of the classical
in vivo test guidelines.
Despite the availability of a comprehensive data set, FET
data are still not considered by regulatory authorities as a direct
alternative to standard fish acute toxicity data, with the Euro-
pean Chemicals Agency citing that “a lack of quality data makes
it challenging to conclude on several aspects of the applicability
domain” (2016). The FET and other alternative data will gain
wider acceptance if data from various methods are considered
in combination—as part of so‐called weight‐of‐evidence ap-
proaches (defined in European Chemicals Agency 2017b;
also see European Chemicals Agency 2017d; Organisation for
Economic Co‐operation and Development 2019b). Examples of
the successful use of combination approaches have just started
to emerge under REACH (Supplemental Data 2). The practical
implementation of the FET within a combination approach has
started to be explored (Lillicrap et al. 2020; HUGIN SWiFT n.d.).
A current OECD project is also examining the potential to in-
corporate the FET into the threshold approach (discussed in the
section Refinement and reduction opportunity: Reducing the
number of test groups), as part of an integrated approach to
testing and assessment (IATA) to minimize testing on juvenile or
adult fish (unpublished data). Data from assays such as the
RT‐gill cell line may also be incorporated into the IATA. Once
published, the IATA approach would still need to be adopted
within regulatory frameworks before it could be applied in
practice. The key consideration before this happens is whether
the combination approach can sufficiently protect the environ-
ment from the potential impacts of chemicals—no attempts to
our knowledge have been made to assess how well even tra-
ditional methods achieve this. For sectors such as the cosmetics
industry, the option to fall back on in vivo study data no longer
exists, at least in the assessment of human health effects. In a
hypothetical situation where fish acute toxicity tests were no
longer an option across all sectors, what would the new data
package look like? In practice, changes in safety‐assessment
practices will realistically need to be driven top‐down by legis-
lative and regulatory change.
Question 3: Can standard studies be reduced
and refined?
In the shorter term, where standard studies remain abso-
lutely necessary, key opportunity areas center around 1) re-
ducing the number of studies conducted and the number of
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animals used within studies and 2) refining the tests to decrease
the suffering experienced by the test animals.
Reduction opportunity: Harmonizing global test
guidelines and regulatory requirements
Because most new substances/products are developed for
global use, data packages are usually generated to meet the
data requirements of all the regions and countries for which
registration and marketing are intended (see Table 1). The
most commonly used fish acute toxicity guideline for pro-
spective assessments globally is OECD test guideline 203
(Figure 1). Under the Mutual Acceptance of Data (MAD)
agreement, when an OECD test guideline is conducted in one
adherent country under GLP, the data generated will be
accepted in other countries adhering to MAD—with the aim of
avoiding test duplication. Recent estimates predicted that
MAD reduces the number of animals needed in testing new
industrial chemicals by 32 702 (Organisation for Economic
Co‐operation and Development 2019c). Despite adhering to
MAD, some geographical regions specify a preference for
other standardized methods (e.g., US Environmental
Protection Agency 2016a), which can have marked differences
in study designs—translating to variations in the overall
number of fish used (see Supplemental Data 3; n.b., part of
the rationale for the last revision of test guideline 203 was to
improve harmonization with the US guideline). There are
some examples of non‐OECD member countries adopting
OECD test guidelines or having their own but virtually iden-
tical protocols which specify differences such as test
species (Table 1). It can also be the case, such as in China
(ChemicalWatch 2019), that testing must be conducted within
the country of registration using local species. There is no
guarantee that data generated in non‐OECD member
countries will be accepted in other regions.
Reducing the number of fish species used in PPP
testing. The acute toxicity testing of PPPs is a prime example
where differing regional requirements drive high fish use be-
cause 4 or more different species may be required for truly
global registrations (Table 1). The test species required in dif-
ferent regions is guided by a range of considerations, including
the intended application of the chemical; differing environ-
mental exposure scenario(s) (for example, likely release into
fresh or saltwater); commercially or ecologically important
species in a given region; or special conservation measures for
certain groups of endangered freshwater, estuarine, or marine
species (see Table 1). It may be the case, however, that testing
of the same substance in multiple fish species is not necessary if
they all share the same key biological pathways resulting in
adverse effects (Ankley et al. 2010; Groh and Tollefsen 2015).
Understanding the similarities and differences in xenobiotic
metabolism in different fish species is also important here
(Kleinow et al. 1987; Nichols et al. 2007).
The key needs are to 1) better understand and/or 2) account
for differences in species sensitivity. In reference to point 1,
some investigations have been made to explore differences in
sensitivity to acute effects in different fish species. Several pa-
pers suggest that rainbow trout (Oncorhynchus mykiss) is the
most sensitive species across a diverse range of chemicals
(Dyer et al. 1997, 2006; Lammer et al. 2009), and the authors
question the need for separate testing of tropical fish species.
An analysis conducted by the European Food Safety Agency
(2006) also showed that rainbow trout was generally the most
sensitive species (though the comparator species was not the
same for each substance, and caution should be exercised in
the interpretation of these data). The sensitivity of saltwater
versus freshwater fish has also been compared (Hutchinson
et al. 1998; Leung et al. 2001; Wheeler et al. 2002, 2014;
Maltby et al. 2005) with this literature, suggesting that saltwater
and freshwater fish are similarly sensitive. In line with this there
has been a rationalization of testing requirements in certain
regions. For PPP active substances in Europe only a fish acute
toxicity test conducted using rainbow trout is now required
(European Commission 2013), where previously a warm‐water
species was also mandatory (European Commission 1991). The
USEPA in collaboration with the National Toxicology Program's
Interagency Center for the Evaluation of Alternative Toxico-
logical Methods is currently conducting a retrospective analysis
project to assess whether current US regulatory requirements
for the testing of warm‐ and cold‐freshwater plus estuarine/
marine fish can be reduced to 2 or even one species (National
Toxicology Program 2020). To point 2, part of the reason for
applying “assessment factors” to the lowest (eco)toxicity value
in the derivation of predicted‐no‐effect concentration is to ac-
count for variability in species sensitivity. Where species sen-
sitivity differences are not anticipated, additional species
testing should not be required because the degree of sensi-
tivity difference should in theory fall within the variation ac-
counted for by the assessment factor. Greater consideration of
likely exposure scenarios can also reduce the number of spe-
cies used for testing (as discussed in the section Reducing the
number of fish species in PPP testing). This is currently an op-
tion in the United States; if, for example, a PPP is not going to
be applied in regions adjacent to mangroves, it may be pos-
sible to waive testing in a saltwater species.
Clearly, individual regional provisions that reduce the number
of fish species tested are likely to have a limited impact on the
3Rs. Global harmonization of vertebrate regulatory requirements
is needed, but this will be a difficult and slow process because
local legal and societal needs must be considered.
Reducing the need for formulation testing. For some
substance types, likely environmental exposure scenarios mean
that fish acute testing of finished/formulated products is not a
standard requirement (Table 1)—for example, human medi-
cines are most likely to enter the environment following patient
use (German Advisory Council on the Environment 2007)
having undergone significant modification from the ad-
ministered formulated product. However, PPP active sub-
stances may be used in differing formulations with, for
example, slight differences in the adjuvants/solvents used; and
under some regional requirements each mixture must be as-
sessed independently (Table 1). This often requires that in vivo
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data be generated for each formulation. This is despite evi-
dence that tests conducted with the active substance could
potentially predict the formulation toxicity (Schmuck
et al. 1994) and that most formulations are not expected to
exhibit more than additive toxicity compared with their con-
stituent active substance components (Creton et al. 2014).
Even where there are provisions to waive testing of
“similar” formulations, in practice this can be challenging. For
example, the European Union PPP regulation (European
Commission 2009a) states that fish acute toxicity testing shall
be performed where the acute toxicity of the PPP cannot be
predicted on the basis of the data for the active substance and
extrapolation on the basis of available data for a similar PPP is
not possible. However, there is a lack of agreed guidance on
how to robustly demonstrate that a preparation is sufficiently
similar or that toxicity can be reliably predicted. There are al-
ready ongoing efforts to decrease the need for mammalian
acute toxicity testing of formulations for human health assess-
ments. This includes a program by the USEPA to evaluate the
ability of the Globally Harmonised System of Classification and
Labelling of Chemicals dose additives mixtures equation to
predict acute toxicity categories for PPP formulations/products
(US Environmental Protection Agency 2017; note for classi-
fication and labeling of industrial chemical mixtures in Europe,
hazard classification is already calculated on the basis of the
proportional ecotoxicity of components and their percentage
of concentrations). More sophisticated platforms are also under
development for predicting the toxicity of PPP formulations
(e.g., see National Centre for the Replacement, Refinement
and Reduction of Animals in Research 2018). Similar ap-
proaches for fish acute toxicity data, particularly if the purpose
of data generation is solely hazard identification and classi-
fication, may be viable.
Refinement and reduction opportunity: Reducing the
number of test groups. Limit tests are performed with a
single concentration of 100 mg/L (or limit of solubility) using
7 or more fish. In the absence of mortality, there is at least
99% confidence that the LC50 is greater than the tested
concentration—considered nontoxic to fish for most safety‐
assessment purposes (Organisation for Economic Co‐operation
and Development 2019a). Another way to reduce fish numbers
is through the “threshold approach”—where an initial test is
carried out in fish at one concentration selected based on the
results of Daphnia and algae toxicity tests. The full response
concentration series is only triggered if mortality is observed at
this threshold concentration. Retrospective data analysis has
demonstrated that a reduction of between approximately 38
and 73% of fish use could be achieved using a threshold ap-
proach, depending on the sector (Hutchinson et al. 2003; Jeram
et al. 2005; Creton et al. 2014). It can also be viewed as a re-
finement because high doses need not be tested so often. The
approach works well for risk assessments which consider the
aquatic compartment as a whole, where endpoints are combined
to derive an assessment that is applied to the lowest value from
the different taxa. However, its application can be complicated
for regulations that require risk assessments for individual taxa
because varying assessment factors and refinements may be
needed (Creton et al. 2014). It has been suggested that FET data
could be used in concentration range‐finding (Rufli and
Springer 2011; Rawlings et al. 2019; Organisation for Economic
Co‐operation and Development 2019a), although the logistics of
incorporating such testing strategies into commercial operations
would be challenging (related to scheduling, analytical
verification, etc., and the limited number of laboratories offering
FET as a routine assay currently because of the lack of regulatory
need and thus industry demand). It is unclear how widely
threshold approaches are currently being applied in practice.
Test substances often require the use of solvents to aid
dissolution, and typically a solvent control group is included in
the study in addition to the dilution water control. Following
the recent OECD test guideline 203 revision, there is now the
option to omit the dilution water control group when a solvent
is used, decreasing the number of fish used by 7 per test
(Organisation for Economic Co‐operation and Development
2019a). The OECD has an ongoing project to determine the
statistical power of test guideline 203 studies with solely a
solvent control, and results indicate that there is no need to
include a water control (unpublished data). It is not clear yet
how widely such an approach will be accepted across different
regulatory authorities/jurisdictions, particularly those which
prefer non‐OECD test guidelines. The recently updated OECD
guidance document 23 on aqueous‐phase aquatic toxicity
testing of difficult test chemicals (Organisation for Economic
Co‐operation and Development 2019d) includes revisions to
reduce occasions when solvents need to be used for poorly
water‐soluble substances. This includes better use of different
generator systems for dosing, including passive dosing
methods. Where solvent use is avoided, the solvent control
group is not necessary. However, it should be acknowledged
that there are situations where solvent‐assisted test item de-
livery is required to achieve appropriate exposure and ensure
that a valid test is performed (Green and Wheeler 2013). In
such cases, it is better to have employed a solvent control and
deliver a robust study that does not subsequently need re-
peating. The provision of improved technical guidance such as
the updated guidance document 23 can also help to reduce
the need to repeat studies by supporting the fulfillment of
recommendations or validity criteria within test guidelines
(Burden et al. 2017).
Refinement opportunity: Using humane/early
endpoints in place of lethality
Early euthanasia of moribund fish is often practiced in
Europe and Canada (with European Union Directive 2010/63/
EU stating that death should be “substituted by more humane
endpoints using clinical signs that determine the impending
death” [European Commission 2010]). Humane endpoints
are defined by the OECD as “the earliest indicator in an animal
experiment of severe pain, severe distress, suffering, or im-
pending death” (Organisation for Economic Co‐operation and
Development 2000). The routine, global use of “sublethal”
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TABLE 3: Summary of examples of how key 3Rs opportunities could be harnessed
Aim Approach Notes and considerations
Accelerating the acceptance of alternative approaches
To build confidence in the predictive
value of alternative approaches
Implementation of “safe haven” approaches (Sewell
et al. 2017b) where registrants submit both
standard fish acute toxicity data in parallel with
packages which utilize multiple lines of evidence
generated using nontraditional methods (cf. the
International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for
Human Use trial for new approaches to
carcinogenicity assessment [European Medicines
Agency 2016]).
Places a relatively high financial and resource
burden on industry and requires cross‐industry
alignment in the approaches applied.
Regulatory agencies would need to be open to
and encouraging of such an approach and enter
into formal agreements to retrospectively assess
and publish scenarios where the nonstandard
approaches are acceptable.
Increase proficiency/capacity to conduct
nonstandard approaches in contract laboratories.
Currently challenging because of lack of regulatory
need/industry demand. May be incentivized by
provision of safe haven approaches.
Collect case studies on registered chemicals where
alternative information types have been
generated/used successfully. This could involve a
“blinded” comparison of regulatory decisions/
outcomes based on traditional vs alternative data.
This would also support the definition of the
applicability domain of alternative approaches
(based, e.g., on chemical class or mode of
action).
Support regulatory bodies in interpretation of
integrated approaches to testing and assessment–
style assessments for the fish acute toxicity
endpoint, drawing on the new tools available.
This would be aided by the provision of relevant
and clear guidance.
Improving global harmonization of data requirements
To definitively determine whether 1)
multiple species in PPP and biocide
testing and 2) formulation in
addition to active substance testing
is needed and, where appropriate,
align global data requirements.
Conduct retrospective data analysis to determine
the difference in interspecies sensitivity on a range
of compounds encompassing a broad range of
modes of action that have been tested on a range
of fish species. This should allow conclusions to be
made on whether there is a generally sensitive fish
species on which the application of assessment
factors would provide suitable levels of protection.
Such an analysis should, if possible, also consider
whether there are any significant differences in
marine, brackish, freshwater, cold‐water, or
warm‐water species and whether there is a
difference between classes or subclasses of fish.
Publicly available databases that may be drawn
from, such as the EnviroTox database (Connors
et al. 2019) and the OECD's eChem portal.
Conduct retrospective data analysis comparing the
acute toxicity of a range of different formulation
types with the same active substance tested in the
same species, to determine whether there are any
patterns and if any general rules can be
established.
Further exploration of the use of reliable prediction
methods (e.g., machine learning techniques),
particularly for hazard identification and
classification where substances are assigned into
broad categories.
Calculated formulation toxicity could be compared
with existing in vivo formulation testing data to
validate the calculation approach. Guidance
would then be prepared to advise on when a
preparation is sufficiently similar to the active
substance, negating the need for new testing.
Prediction approaches may also be applicable to
assess the toxicity of metabolites/degradation
products, particularly for PPPs. This has started
to be explored using QSAR models (see
Question 2: Can standard fish acute toxicity
studies be replaced?; Burden et al. 2016).
Reducing/refining animal use in mandatory in vivo studies
To increase the uptake of the
threshold approach and use of
humane endpoints in place of
lethality.
Identify the extent of and barriers to uptake of the
threshold approach within industry and regulatory
bodies, and devise efforts to overcome these.
Establish who will be responsible for collating
sublethal clinical signs data with the cooperation
of industry (as owners of the data).
Conduct data analysis (retrospectively and through
prospective data collection) to determine which
sublethal signs are relevant and predictive and
could be used as the modified endpoint.
These aspects were the subject of discussion at the
2020 UK‐Defra‐funded workshop (manuscript in
preparation).
This will require consistency between laboratories
regarding identification and recording of signs
within individual fish, which may not be possible
retrospectively.
Critical that there is global agreement on the
standard use and definition of humane
endpoints so as not to undermine the mutual
acceptance of data agreement if some countries
continue to require the lethality endpoint (note
the authors have not experienced this to be the
case to date).
Defra=Department for Environment, Food and Rural Affairs; OECD=Organisation for Economic Co‐operation and Development; PPP= plant protection product;
QSAR= quantitative structure–activity relationship.
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humane endpoints in place of death would substantially reduce
the degree of suffering experienced by test animals. It may also
be considered more environmentally relevant and indicative of
“ecological death”—in the wild these fish would not survive
(e.g., because of predation). There is already a precedent in
mammalian acute toxicity testing where “evident toxicity” is
used as the endpoint in place of death (e.g., Organisation for
Economic Co‐operation and Development 2002, 2017b, 2018;
Sewell et al. 2015). “Evident toxicity” is defined as clear signs
of toxicity without causing severe toxic effects or mortality,
which predict that exposure to the next highest concentration
will cause severe toxicity or death/moribundity in most animals.
There is, however, no international consensus on which sublethal
clinical signs define moribundity or are predictive of death in
fish. Early termination of studies when fish are showing signs of
“considerable suffering” is featured in other test guidelines, but
these are designed to examine less severe endpoints, for ex-
ample, OECD 240 (Organisation for Economic Co‐operation and
Development 2015). The 2019 revision to OECD test guideline
203 requires the recording of certain sublethal clinical signs, with
the option to record further/more detailed signs. The aim of
collecting these data is to enable the development of detailed
guidance on how to identify when individual fish should be
humanely terminated before the end of the test. A UK Depart-
ment for the Environment, Food and Rural Affairs–sponsored
expert workshop was held in early 2020 with the aim of identi-
fying the knowledge gaps impeding the standardized recording
and reporting of sublethal clinical signs of toxicity in fish and
ultimately moving away from using mortality as the endpoint in
OECD test guideline 203. It is critical that the signs identified are
genuinely predictive of death because the use of humane
endpoints could affect experimental endpoint outcome
by lowering LC50 values. Lower LC50 values could trigger
unnecessary higher‐tier testing within the same risk assessment
framework and lead to the use of more animals.
HARNESSING THE OPPORTUNITIES
The present exploration of the current situation has identi-
fied opportunities for further work to reduce uncertainty in key
areas and genuinely support greater application of the 3Rs.
This will only occur if strong scientific evidence is provided
which demonstrates that protection goals will not be compro-
mised. Table 3 summarizes examples of how these oppor-
tunities could be harnessed, under the themes of accelerating
the acceptance of alternative approaches, improving global
harmonization of data requirements, and reducing/refining
within mandatory in vivo studies.
IN SUMMARY
There is undoubtedly value in the different industry and
regulatory sectors coming together in this unique way to share
experiences and explore how approaches applied in one sector
may be applicable to another. A key example includes consid-
ering the wider relevance and application of exposure‐driven
approaches. For some sectors, such as the cosmetics industry,
generating in vivo data is already legally no longer an option in
many regions to assess human health effects, and absolute re-
placements must be utilized to address safety concerns. Global
harmonization of requirements is paramount in maximizing the
3Rs impact on regulatory change. Pertinent questions remain: 1)
Can alternative approaches be used in existing or modified
regulatory hazard and/or risk assessment schemes to achieve at
least the same level of protection compared with current
practices (and if the appropriate level of protection is not af-
forded, what would be required to ensure that it is)? 2) What is
actually needed to address perceived data gaps? There are
further scientific reasons for reconsidering the current paradigm,
to meet the challenges that changing environmental landscapes
and technologies will raise. Ultimately, change in practice needs
to be driven by a “top‐down” approach which compels the
community to think differently—in line with the recent commit-
ment by the USEPA to eliminate mammalian safety testing by
2035. It is the perfect time to reflect on the current situation and
consider how to make best use of the new techniques and
approaches available, while still ensuring that testing is science‐
driven and protective—to genuinely reduce the number of
fish experiencing severe suffering in the quest to assess
chemical‐induced acute toxicity.
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